ElevateBio Raises $401m To Fund Its Own And Partners’ Future Cell And Gene Therapy Needs
$1.3bn Invested In R&D, Manufacturing One-Stop Shop To Date
ElevateBio closed a series D venture capital round and revealed a potentially multibillion-dollar deal between its Life Edit subsidiary and Novo Nordisk as demand for its cell and gene therapy capabilities grow.
You may also be interested in...
Struggling antibiotic company will go privare under the agreement. Bayer will employ Acuitas's liquid nanoparticle technology in gene therapies developed by subsidiary Asklepios.
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.
With Vida Ventures and Leaps by Bayer leading the round, Affini-T raises $175m to advance its KRAS-targeted T-cell therapies into the clinic and add technological capabilities.